[HTML][HTML] Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation
Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
T Wisløff, G Hagen, M Klemp - PharmacoEconomics, 2014 - ideas.repec.org
We have found apixaban or sequential dabigatran to be the alternatives most likely to be
considered cost effective, depending on the switching age for dabigatran. These …
considered cost effective, depending on the switching age for dabigatran. These …
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
T Wisløff, G Hagen, M Klemp - PharmacoEconomics, 2014 - infona.pl
Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation.
T Wisløff, G Hagen, M Klemp - PharmacoEconomics, 2014 - search.ebscohost.com
Background: Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
T Wisløff, G Hagen, M Klemp - PharmacoEconomics, 2014 - search.proquest.com
Atrial fibrillation (AF) is a major risk factor for stroke, which causes thousands of deaths and
sequelae. It is recommended that AF patients at medium or high risk of stroke use an oral …
sequelae. It is recommended that AF patients at medium or high risk of stroke use an oral …
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation
T Wisløff, G Hagen, M Klemp - PharmacoEconomics, 2014 - pubmed.ncbi.nlm.nih.gov
Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
T Wisløff, G Hagen, M Klemp - Pharmacoeconomics, 2014 - europepmc.org
Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
[HTML][HTML] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
T Wisløff, G Hagen, M Klemp - Pharmacoeconomics, 2014 - ncbi.nlm.nih.gov
Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
[PDF][PDF] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
T Wisløff, G Hagen, M Klemp - PharmacoEconomics, 2014 - Citeseer
Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
T Wisløff, G Hagen, M Klemp - PharmacoEconomics, 2014 - econpapers.repec.org
We have found apixaban or sequential dabigatran to be the alternatives most likely to be
considered cost effective, depending on the switching age for dabigatran. These …
considered cost effective, depending on the switching age for dabigatran. These …